Literature DB >> 20472504

In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.

Benigno Rodriguez1, Hernan Valdez, Christoph G Lange, Robert Asaad, Kathy Medvik, Scott F Sieg.   

Abstract

Immune reconstitution after HAART is incomplete, but no widely accepted method to quantify subclinical immune deficiency is available. We immunized 9 HIV-negative subjects and 29 HIV-infected patients with CD4>/=450 cells/microL and undetectable HIV RNA levels with 2 doses of diphtheria/tetanus toxoid (TT) and KLH, a presumed neoantigen. We quantified the response by lymphoproliferative assay, delayed-type hypersensitivity (DTH), and antibody titers up to 59days after enrollment. We assessed T cell proliferative capacity using anti-Vbeta3 and anti-Vbeta5 antibody stimulation, which we herein show induced predominant proliferation of naïve T cells. Subjects with detectable responses to KLH tended to exhibit greater proliferative responses to anti-Vbeta3/Vbeta5 stimulation; no such pattern was seen with response to TT. Several measures of in vitro T cell proliferative capacity correlated significantly with DTH and antibody responses to KLH, but not with TT responses; this association was independent of naïve T cell numbers. Our results indicate that naïve T cell proliferation predicts response to neo-, but not recall antigens, and suggest that it may be a meaningful reflection of in vivo immune competence in HIV-infected persons. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472504      PMCID: PMC2917530          DOI: 10.1016/j.clim.2010.04.016

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  43 in total

1.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.

Authors:  C J Pitcher; C Quittner; D M Peterson; M Connors; R A Koup; V C Maino; L J Picker
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

3.  Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression.

Authors:  M T Roos; F Miedema; A P Meinesz; N A De Leeuw; N G Pakker; J M Lange; R A Coutinho; P T Schellekens
Journal:  Clin Exp Immunol       Date:  1996-09       Impact factor: 4.330

Review 4.  NK cells in HIV infection: paradigm for protection or targets for ambush.

Authors:  Anthony S Fauci; Domenico Mavilio; Shyam Kottilil
Journal:  Nat Rev Immunol       Date:  2005-11       Impact factor: 53.106

5.  Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men.

Authors:  P T Schellekens; M T Roos; F De Wolf; J M Lange; F Miedema
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

6.  T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects.

Authors:  M T Roos; F Miedema; M Koot; M Tersmette; W P Schaasberg; R A Coutinho; P T Schellekens
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

7.  Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS.

Authors:  M T Roos; M Prins; M Koot; F de Wolf; M Bakker; R A Coutinho; F Miedema; P T Schellekens
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

8.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

Review 9.  Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity.

Authors:  R S Kalish; P W Askenase
Journal:  J Allergy Clin Immunol       Date:  1999-02       Impact factor: 10.793

10.  HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Authors:  Antonella d'Arminio Monforte; Donald Abrams; Christian Pradier; Rainer Weber; Peter Reiss; Fabrice Bonnet; Ole Kirk; Matthew Law; Stephane De Wit; Nina Friis-Møller; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.632

View more
  3 in total

1.  Frequencies of FoxP3+ naive T cells are related to both viral load and naive T cell proliferation responses in HIV disease.

Authors:  Benigno Rodriguez; Douglas A Bazdar; Nicholas Funderburg; Robert Asaad; Angel A Luciano; Gopal Yadavalli; Robert C Kalayjian; Michael M Lederman; Scott F Sieg
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

2.  The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment.

Authors:  Tammy M Rickabaugh; Ryan D Kilpatrick; Lance E Hultin; Patricia M Hultin; Mary Ann Hausner; Catherine A Sugar; Keri N Althoff; Joseph B Margolick; Charles R Rinaldo; Roger Detels; John Phair; Rita B Effros; Beth D Jamieson
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

3.  Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.

Authors:  Denise C Hsu; Stephen J Kerr; Thatri Iampornsin; Sarah L Pett; Anchalee Avihingsanon; Parawee Thongpaeng; John J Zaunders; Sasiwimol Ubolyam; Jintanat Ananworanich; Anthony D Kelleher; David A Cooper
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.